Biological drug use: US perspectives on indications and monitoring

Por Cush, J
Publicado em 2005

Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents

Por Furst, D, Cush, J, Kaufmann, S, Siegel, J, Kurth, R
Publicado em 2002

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

Por Bykerk, V P, Cush, J, Winthrop, K, Calabrese, L, Lortholary, O, de Longueville, M, van Vollenhoven, R, Mariette, X
Publicado no Ann Rheum Dis (2015)

A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis trea...

Por Cohen, S, Moreland, L, Cush, J, Greenwald, M, Block, S, Shergy, W, Hanrahan, P, Kraishi, M, Patel, A, Sun, G, Bear, M
Publicado em 2004

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

Por Davis, J, van der Heijde, D M, Braun, J, Dougados, M, Cush, J, Clegg, D, Inman, R, Kivitz, A, Zhou, L, Solinger, A, Tsuji, W
Publicado em 2005